MA34968B1 - Urées asymétriques et utilisations médicales de celles-ci - Google Patents

Urées asymétriques et utilisations médicales de celles-ci

Info

Publication number
MA34968B1
MA34968B1 MA36252A MA36252A MA34968B1 MA 34968 B1 MA34968 B1 MA 34968B1 MA 36252 A MA36252 A MA 36252A MA 36252 A MA36252 A MA 36252A MA 34968 B1 MA34968 B1 MA 34968B1
Authority
MA
Morocco
Prior art keywords
medical uses
asymmetric urea
asymmetric
urea
compounds
Prior art date
Application number
MA36252A
Other languages
English (en)
Inventor
Rubio Silvina Garcia
Claudio Pietra
Claudio Giuliano
Zhigang Li
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Publication of MA34968B1 publication Critical patent/MA34968B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La présente invention concerne des composés, des compositions et des procédés pour la prévention et/ou le traitement de maladies qui sont médiées de façon physiopathologique par le récepteur de ghréline. Les composés ont la formule générale (I).
MA36252A 2011-02-25 2012-02-23 Urées asymétriques et utilisations médicales de celles-ci MA34968B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/CN2011/000298 WO2012113103A1 (fr) 2011-02-25 2011-02-25 Urées asymétriques et leurs utilisations médicales
US201161466070P 2011-03-22 2011-03-22
PCT/US2012/026315 WO2012116176A2 (fr) 2011-02-25 2012-02-23 Urées asymétriques et utilisations médicales de celles-ci

Publications (1)

Publication Number Publication Date
MA34968B1 true MA34968B1 (fr) 2014-03-01

Family

ID=46719417

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36252A MA34968B1 (fr) 2011-02-25 2012-02-23 Urées asymétriques et utilisations médicales de celles-ci

Country Status (39)

Country Link
US (3) US8658797B2 (fr)
EP (1) EP2678017B1 (fr)
JP (1) JP6077468B2 (fr)
KR (2) KR101907573B1 (fr)
CN (2) CN103874492B (fr)
AP (1) AP3768A (fr)
AR (1) AR085398A1 (fr)
AU (1) AU2012220531B2 (fr)
BR (1) BR112013021566B1 (fr)
CA (1) CA2820767C (fr)
CL (1) CL2013002412A1 (fr)
CO (1) CO6771450A2 (fr)
CY (1) CY1118947T1 (fr)
DK (1) DK2678017T3 (fr)
DO (1) DOP2013000195A (fr)
EA (1) EA027374B1 (fr)
EC (1) ECSP13012893A (fr)
ES (1) ES2628386T3 (fr)
GE (1) GEP20156319B (fr)
HR (1) HRP20170997T1 (fr)
HU (1) HUE035039T2 (fr)
IL (1) IL227941A (fr)
LT (1) LT2678017T (fr)
MA (1) MA34968B1 (fr)
ME (1) ME02845B (fr)
MX (1) MX347587B (fr)
MY (1) MY164354A (fr)
NI (1) NI201300070A (fr)
PE (1) PE20141000A1 (fr)
PL (1) PL2678017T3 (fr)
PT (1) PT2678017T (fr)
RS (1) RS56033B1 (fr)
SG (1) SG192138A1 (fr)
SI (1) SI2678017T1 (fr)
TN (1) TN2013000346A1 (fr)
TW (1) TWI579273B (fr)
UA (1) UA113510C2 (fr)
WO (2) WO2012113103A1 (fr)
ZA (1) ZA201307071B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012113103A1 (fr) * 2011-02-25 2012-08-30 Helsinn Healthcare S.A. Urées asymétriques et leurs utilisations médicales
EA038645B1 (ru) 2012-12-21 2021-09-28 Авео Фармасьютикалз, Инк. Антитела к gdf15
TWI703130B (zh) 2014-03-07 2020-09-01 瑞士商赫爾辛保健股份有限公司 對位取代的不對稱脲及其醫療用途
RU2686317C2 (ru) * 2015-04-24 2019-04-25 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Замещенные 1,2,5-триметил- и 2,2,6,6-тетраметил-4-аминопиперидины, обладающие антиишемическим действием
CA3017048C (fr) 2016-03-22 2023-11-07 Helsinn Healthcare Sa Urees asymetriques de benzenesulfonyle et leurs utilisations medicales
KR20200041336A (ko) * 2017-08-07 2020-04-21 고쿠리츠다이가쿠호진 히로시마다이가쿠 지방성 간 질환의 치료제 및 비만증의 치료제
BR112020003477A2 (pt) 2017-08-21 2020-08-25 Acadia Pharmaceuticals, Inc. compostos e método para tratar uma doença
WO2019040104A2 (fr) 2017-08-21 2019-02-28 Acadia Pharmaceuticals Inc. Composés, sels associés et méthodes de traitement de maladies
BR112020010803A2 (pt) 2017-12-11 2020-11-10 Helsinn Healthcare Sa sal, (r)-3-(1-(2,3-dicloro-4-(pirazin-2-il)fenil)-2,2,2-trifluoroetil)-1-metil-1-(1-metilpiperidin-4-il) uréia cristalino, produto de medicamento, composição, método para preparar o sal e usos do sal
EP3542799A1 (fr) 2018-03-22 2019-09-25 Helsinn Healthcare SA Nouvel agoniste de la ghréline centralement actif et ses utilisations médicales
BR112023025327A2 (pt) 2021-06-02 2024-02-27 Anacardio Ab Método para tratar uma condição que requer tratamento inotrópico

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5285174A (en) * 1976-01-05 1977-07-15 Yoshitomi Pharmaceut Ind Ltd Novel urea or thiourea derivatives
AU7545894A (en) 1993-09-02 1995-03-22 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
WO1998006709A1 (fr) 1996-08-14 1998-02-19 Takeda Chemical Industries, Ltd. Composes d'urees cycliques, leur production et leur utilisation comme herbicides
US6399619B1 (en) 1999-04-06 2002-06-04 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
JP4664564B2 (ja) * 2000-03-06 2011-04-06 アカディア ファーマシューティカルズ，インコーポレーテッド セロトニン関連疾患の治療に使用する含窒素環式化合物
GB0011838D0 (en) * 2000-05-17 2000-07-05 Astrazeneca Ab Chemical compounds
US20030022891A1 (en) * 2000-12-01 2003-01-30 Anandan Palani MCH antagonists and their use in the treatment of obesity
US20040110952A1 (en) 2001-03-01 2004-06-10 Jeremy Burrows N-4-piperidinyl compounds as ccr5 modulators
GB0107228D0 (en) 2001-03-22 2001-05-16 Astrazeneca Ab Chemical compounds
US6673829B2 (en) * 2001-09-14 2004-01-06 Novo Nordisk A/S Aminoazetidine,-pyrrolidine and -piperidine derivatives
SE0103818D0 (sv) 2001-11-15 2001-11-15 Astrazeneca Ab Chemical compounds
SE0200919D0 (sv) 2002-03-25 2002-03-25 Astrazeneca Ab Chemical compounds
AU2003268493A1 (en) * 2002-09-11 2004-04-30 Merck & Co., Inc. Piperazine urea derivatives as melanocortin-4 receptor agonists
AU2003284402A1 (en) 2002-11-15 2004-06-15 Yamanouchi Pharmaceutical Co., Ltd. Antagonist to melanin-concentrating hormone receptor
JP4384635B2 (ja) * 2003-06-30 2009-12-16 住友化学株式会社 不斉尿素化合物およびこれを触媒として用いる不斉共役付加反応による不斉化合物の製造方法
US7115767B2 (en) * 2003-07-18 2006-10-03 Abbott Laboratories Tetraline derivatives as ghrelin receptor modulators
US20050209232A1 (en) * 2004-02-10 2005-09-22 Kent Barbay Pyridazinone ureas as antagonists of alpha4 integrins
US20050261278A1 (en) * 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
GB0412865D0 (en) 2004-06-09 2004-07-14 Glaxo Group Ltd Chemical compounds
SE0401657D0 (sv) 2004-06-24 2004-06-24 Astrazeneca Ab Chemical compounds
SE0401971D0 (sv) * 2004-08-02 2004-08-02 Astrazeneca Ab Piperidne derivatives
WO2006020959A2 (fr) * 2004-08-13 2006-02-23 Amgen Inc. Heterocycles benzo-condenses substitues
CA2575764A1 (fr) * 2004-10-27 2006-05-11 Neurogen Corporation Diaryl urees, antagonistes du cb1
US20080306055A1 (en) 2004-12-21 2008-12-11 Astrazeneca Ab Heterocyclic Mchr1 Antagonists And Their Use In Therapy
US7829589B2 (en) 2005-06-10 2010-11-09 Elixir Pharmaceuticals, Inc. Sulfonamide compounds and uses thereof
US20080300251A1 (en) * 2005-09-05 2008-12-04 Sattigeri Jitendra A Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors
EP1948190A2 (fr) * 2005-11-01 2008-07-30 Transtech Pharma Utilisation pharmaceutique des amides substitués
AR058277A1 (es) * 2005-12-09 2008-01-30 Solvay Pharm Gmbh N- sulfamoil - piperidin - amidas, composiciones farmaceuticas que las comprenden y procedimiento para su preparacion
AU2007273057A1 (en) 2006-07-12 2008-01-17 Merck Sharp & Dohme Corp. Substituted pyrazoles as ghrelin receptor antagonists
JP2008042298A (ja) 2006-08-02 2008-02-21 Olympus Corp 固体撮像装置
GB0701992D0 (en) 2007-02-02 2007-03-14 7Tm Pharma As Grehlin Receptor Modulators
US20080280886A1 (en) * 2007-05-08 2008-11-13 Auspex Pharmaceuticals, Inc. Substituted ureas
GB0710863D0 (en) 2007-06-06 2007-07-18 Glaxo Group Ltd Novel compounds
GB0710865D0 (en) 2007-06-06 2007-07-18 Glaxo Group Ltd Novel compounds
WO2009020960A1 (fr) 2007-08-06 2009-02-12 The Regents Of The University Of California Préparation d'urées 1,3-substituées novatrices en tant qu'inhibiteurs d'époxyde hydrolase soluble
DK2200610T3 (en) * 2007-09-21 2018-04-23 Acadia Pharm Inc ADMINISTRATION OF PIMAVANSERIN WITH OTHER AGENTS
UA100527C2 (en) 2007-10-10 2013-01-10 Астразенека Аб Benzothiazoles as ghrelin receptor modulators
WO2009092293A1 (fr) 2008-01-18 2009-07-30 Shanghai Targetdrug Co., Ltd. Composés à base de pyrollidine
WO2009089659A1 (fr) 2008-01-18 2009-07-23 Shanghai Targetdrug Co., Ltd. Composés à base de pyrollidine
USRE49686E1 (en) * 2008-09-19 2023-10-10 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound and use of same
WO2010111353A1 (fr) * 2009-03-25 2010-09-30 Acadia Pharmaceuticals, Inc. Dérivés de pipéridine n-substitués en tant qu'agents spécifiques des récepteurs de la sérotonine
WO2011060397A1 (fr) * 2009-11-16 2011-05-19 Schering Corporation Amino heterocycles substitues utilises comme antagonistes du vih
WO2012113103A1 (fr) * 2011-02-25 2012-08-30 Helsinn Healthcare S.A. Urées asymétriques et leurs utilisations médicales

Also Published As

Publication number Publication date
NI201300070A (es) 2014-03-11
NZ615283A (en) 2015-09-25
PL2678017T3 (pl) 2017-09-29
JP6077468B2 (ja) 2017-02-08
UA113510C2 (uk) 2017-02-10
CN103874492B (zh) 2016-12-07
SG192138A1 (en) 2013-08-30
US10407390B2 (en) 2019-09-10
IL227941A0 (en) 2013-09-30
US20140121210A1 (en) 2014-05-01
DK2678017T3 (en) 2017-07-24
HRP20170997T1 (hr) 2017-10-06
WO2012116176A3 (fr) 2014-04-24
AP3768A (en) 2016-08-31
EP2678017A4 (fr) 2015-05-20
CL2013002412A1 (es) 2014-02-07
US8658797B2 (en) 2014-02-25
MY164354A (en) 2017-12-15
LT2678017T (lt) 2017-06-26
AU2012220531A1 (en) 2013-09-26
KR20140014186A (ko) 2014-02-05
ECSP13012893A (es) 2013-11-29
WO2012116176A2 (fr) 2012-08-30
CY1118947T1 (el) 2018-01-10
EA201300946A1 (ru) 2014-06-30
CO6771450A2 (es) 2013-10-15
ME02845B (fr) 2018-01-20
ZA201307071B (en) 2014-06-25
PT2678017T (pt) 2017-06-26
CA2820767C (fr) 2019-06-25
BR112013021566B1 (pt) 2020-11-17
PE20141000A1 (es) 2014-08-09
CN106995403A (zh) 2017-08-01
JP2014518543A (ja) 2014-07-31
KR101907573B1 (ko) 2018-10-15
CN106995403B (zh) 2020-04-24
US9751836B2 (en) 2017-09-05
KR20180075703A (ko) 2018-07-04
MX2013006974A (es) 2013-10-07
DOP2013000195A (es) 2014-12-15
RS56033B1 (sr) 2017-09-29
AP2013007123A0 (en) 2013-09-30
TWI579273B (zh) 2017-04-21
MX347587B (es) 2017-05-03
SI2678017T1 (sl) 2017-07-31
HUE035039T2 (en) 2018-05-02
EA027374B1 (ru) 2017-07-31
US20120220629A1 (en) 2012-08-30
US20180044293A1 (en) 2018-02-15
BR112013021566A2 (pt) 2016-11-08
AR085398A1 (es) 2013-09-25
WO2012113103A1 (fr) 2012-08-30
CN103874492A (zh) 2014-06-18
AU2012220531B2 (en) 2017-02-23
TW201245151A (en) 2012-11-16
EP2678017B1 (fr) 2017-04-05
ES2628386T3 (es) 2017-08-02
TN2013000346A1 (en) 2015-01-20
IL227941A (en) 2017-10-31
EP2678017A2 (fr) 2014-01-01
GEP20156319B (en) 2015-07-10
CA2820767A1 (fr) 2012-08-30

Similar Documents

Publication Publication Date Title
MA34968B1 (fr) Urées asymétriques et utilisations médicales de celles-ci
MA35836B1 (fr) 4 phényl-pyridines substituées pour le traitement de maladies associées à un récepteur nk-1
PH12020551062A1 (en) 1,2,4-oxadiazole compounds as inhibitors of cd47 signalling pathways
CY1120866T1 (el) Παρεμποδιστες dna-pk
MA39193A1 (fr) Modulateurs du gpr6 à base de tétrahydropyridopyrazines
EA201790806A1 (ru) Иммунорегулирующие средства
MA43169B1 (fr) Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma
MA35920B1 (fr) Composés destinés au traitement de l'amyotrophie spinale
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
EA024842B9 (ru) Соединения в качестве модуляторов протеинкиназы pi3k
EA201500362A1 (ru) Ингибиторы rho-киназы
MX2015006152A (es) Compuestos de aminopirimidina como inhibidores de mutantes de egfr que contienen t7 9 0m.
EA201691135A1 (ru) Новые ингибиторы глутаминазы
EA201990240A1 (ru) Новые трициклические соединения в качестве противораковых средств
EA201491579A1 (ru) Соединения оксазолидин-2-она и их применения в качестве ингибиторов pi3k
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
EA201491592A1 (ru) Соединения индолов и индазолов, активирующие ampk
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201070328A1 (ru) Соединения триазолопиридина и их применение в качестве ингибиторов ask
EA200900983A1 (ru) Соединения и композиции в качестве ингибиторов киназы
EA201291099A1 (ru) Новые иммуномодуляторные и противовоспалительные соединения
EA201490423A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ, ОТНОСЯЩИЕСЯ К p62, ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ РАКА
EA201200570A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201101241A1 (ru) Лечение лейкозов и хронических миелопролиферативных болезней антителами к ерна3
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds